Our Mission
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.

The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.
GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.
Who We Are
GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.
